English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

In addition to being new therapeutic targets, circulating miRNAs has shown great promise as novel biomarkers for cardiovascular disease. Previous reports5–7 indicate that plasma levels of specific miRNAs correlate with arteriosclerotic disicroRNAs (miRNAs) are single-stranded and short noncoding RNAs, typically 19–23 nucleotides in length, generated from endogenous transcripts.1,2 MiRNAs hybridize to mRNAs, resulting in negative regulation of target mRNA stability or translational inhibition of targeted transcripts, and are therefore considered as a key regulator of gene expression.1 To date, more than 1,000 human miRNAs have been identified, and many are suggested to have important roles in a variety of physiological and pathological processes, such as development, differentiation, cell proliferation, apoptosis, and stress responses.2 A growing body of evidence over the past few years suggests the importance of miRNAs in the onset of various diseases such as cancer, neurological diseases, immune diseases and cardiovascular diseases.3 Several studies

Plasma MicroRNA-100 as a Biomarker of Coronary Plaque Vulnerability